Want to see CH:EVE full AI Analyst Report?
Top Page
Evolva Holding
(EVE)
Select Model
Select Model
Rating:53Neutral
Price Target:
CHF2.00
▲(143.90% Upside)
Action:Reiterated
Date:07/10/26
The score is held down primarily by weak financial performance (zero revenue in 2024–2025, inconsistent profitability, and persistent negative operating/free cash flow), only partially offset by a debt-free balance sheet and reduced recent cash burn. Technicals are constructive with the price above key moving averages and positive MACD, but valuation remains challenged due to a negative P/E and no dividend yield data.
Positive Factors
Debt-free balance sheet
The lack of debt from 2023–2025 materially lowers fixed financing costs and preserves strategic flexibility. For a biotech with uneven cash generation, low leverage reduces insolvency risk, limits interest expense drain, and extends runway to pursue partnerships or restructuring without immediate debt-servicing pressure.
Negative Factors
Zero reported revenue (2024–2025)
Reporting zero revenue in 2024–2025 eliminates a durable operating foundation and means no ongoing sales-driven earnings engine. This structural deficiency forces reliance on financing, asset sales, or one-off items, and substantially raises execution risk until a sustainable revenue stream is re-established.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The lack of debt from 2023–2025 materially lowers fixed financing costs and preserves strategic flexibility. For a biotech with uneven cash generation, low leverage reduces insolvency risk, limits interest expense drain, and extends runway to pursue partnerships or restructuring without immediate debt-servicing pressure.
Read all positive factors
Evolva Holding (EVE) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF16.01M
Dividend YieldN/A
Average Volume (3M)6.26K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue GrowthN/A
EPS Growth-162.50%
CountryCH
Employees49
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding7,230,626
10 Day Avg. Volume6,146
30 Day Avg. Volume6,263
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Evolva Holding Business Overview & Revenue Model
Company Description
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, S...
How the Company Makes Money
null...
Evolva Holding Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 9.44M | 15.54M | 9.88M |
| Gross Profit | 0.00 | 0.00 | -4.83M | -8.89M | -9.31M |
| EBITDA | -652.10K | 3.70M | -98.36M | -34.52M | -31.82M |
| Net Income | -652.70K | 1.04M | -105.23M | -43.37M | -41.27M |
Balance Sheet | |||||
| Total Assets | 6.76M | 7.54M | 9.83M | 131.01M | 156.17M |
| Cash, Cash Equivalents and Short-Term Investments | 5.61M | 6.75M | 5.84M | 5.14M | 11.00M |
| Total Debt | 0.00 | 0.00 | 0.00 | 15.06M | 10.84M |
| Total Liabilities | 812.70K | 945.30K | 4.28M | 24.77M | 24.40M |
| Stockholders Equity | 5.94M | 6.60M | 5.55M | 106.24M | 131.77M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -2.44M | -9.72M | -21.13M | -33.57M |
| Operating Cash Flow | -1.14M | -2.44M | -9.25M | -18.88M | -29.79M |
| Investing Cash Flow | 0.00 | 3.52M | 15.95M | -1.76M | -4.64M |
| Financing Cash Flow | 0.00 | -163.10K | -5.97M | 14.77M | 25.72M |
Evolva Holding Technical Analysis
Positive
0.82
Price Trends
1.74
Positive
1.32
Positive
1.09
Positive
Market Momentum
0.12
Positive
56.37
Neutral
60.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:EVE, the sentiment is Positive. The current price of 0.82 is below the 20-day moving average (MA) of 2.19, below the 50-day MA of 1.74, and below the 200-day MA of 1.09, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 56.37 is Neutral, neither overbought nor oversold. The STOCH value of 60.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:EVE.
Evolva Holding Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
53 Neutral | CHF16.01M | -24.56 | -9.73% | ― | ― | -162.50% | |
50 Neutral | CHF240.93M | -18.62 | ― | ― | -63.05% | -187.61% | |
44 Neutral | CHF228.75M | -4.04 | -301.13% | ― | 97.32% | -11.07% | |
43 Neutral | CHF127.58M | -2.03 | -51.05% | ― | -100.00% | 9.23% |
* Financial Sector Average
CH:EVE
Evolva Holding
2.22
1.10
98.21%
CH:MOLN
Molecular Partners AG
3.16
0.05
1.61%
CH:NWRN
Newron Pharmaceuticals SpA
11.58
4.88
72.84%
CH:SANN
Santhera Pharmaceuticals Holding
15.42
0.96
6.64%
CH:XLS
Xlife Sciences Ltd.
17.25
-5.45
-24.01%
Evolva Holding Corporate Events
EvoNext Wins Shareholder Backing for Governance Changes to Pursue Reverse Takeover
May 20, 2026
Shareholders of EvoNext Holdings SA approved all board proposals at the 2026 Annual General Meeting in Zurich, endorsing the 2025 financial statements, carrying forward an accumulated deficit of CHF 341 million, and re-electing key board members a...
EvoNext posts low 2025 cash burn as it pursues reverse takeover and eyes arbitration upside
Apr 29, 2026
EvoNext Holdings SA has released its 2025 full-year report, showing liquidity of CHF 5.9 million, total assets of CHF 6.8 million and equity of CHF 5.9 million, with an underlying annual cash burn below CHF 0.3 million and an operating loss of CHF...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.